April 17, 2023 03:29 PM EDT
Pharma
Manufacturing

FDA in­spec­tion at Lupin man­u­fac­tur­ing site un­cov­ers break­downs left un­in­ves­ti­gat­ed and da­ta ques­tions

Tyler Patchen

News Reporter

A March FDA in­spec­tion at Lupin’s man­u­fac­tur­ing site in Pi­tham­pur, In­dia has un­cov­ered qual­i­ty and oth­er per­for­mance is­sues.

The FDA’s

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times